Bozitinib

SKU: orb1309913

Description

Bozitinib (PLB-1001) is a brain-penetrant, highly selective c-MET kinase inhibitor that targets the ATP-binding site. It is utilized in preclinical oncology research, showing activity in both in vitro assays and in vivo models of cancers with c-MET dysregulation.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1440964-89-5
• MW: 424.38
• Purity: 99.48% (May vary between batches)
• Formula: C₂₀H₁₅F₃N₈
• SMILES: Cn1cc2cc(c(F)cc2n1)C(F)(F)c1nnc2ccc(nn12)-c1cnn(c1)C1CC1
• Target: c-Met/HGFR
• Solubility: DMSO:30 mg/mL (70.69 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.71 mM)

Bioactivity

• In Vitro:
  Bozitinib (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3. Bozitinib has a robust inhibitory effect on MET and its downstream signaling pathways.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, HGFR, inhibit, PLB 1001, PLB1001, PLB-1001, Bozitinib, c-Met/HGFR, cMet/HGFR, c-Met, cMet, CBT 101, CBT101, CBT-101, Vebreltinib

Compound Identifiers

PubChem CID

72202701